By Jonathan Stempel NEW YORK (Reuters) – Pfizer Inc said its fellowship program for minorities serves the public interest, as the drugmaker defends against a lawsuit by a group of medical professionals that claims the program illegally excludes whites and Asian-Americans. In a Tuesday night filing, Pfizer urged a Manhattan federal judge to reject Do No Harm’s request for an injunction against filling the 2023 class for its Breakthrough Fellowship Program, which enrolls Blacks, Latinos and Native Americans. Pfizer said the two-year-old program helps address historical discrimination in the work…